Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
BG-C137 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
BG-C137 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
BG-C137: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
ABBV-1042 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
ABBV-1042 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ABBV-1042: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Anti-CD70 CAR-T (St Jude Children's Research Hospital, Inc) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Anti-CD70 CAR-T (St Jude Children's Research Hospital, Inc) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Anti-CD70 CAR-T (St Jude Children's Research Hospital, Inc): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing de
Read →
EBI-02 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
EBI-02 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
EBI-02: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
HMPL-415S1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
HMPL-415S1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
HMPL-415S1: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
APX-343A Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
APX-343A Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
APX-343A: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
GQ-1007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
GQ-1007 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
GQ-1007: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
HBM-1020 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
HBM-1020 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
HBM-1020: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
Erbumine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
Erbumine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Erbumine: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
M5542 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
M5542 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
M5542: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →
CT1194C CAR-T(Hematology Hospital of Chinese Academy of Medical Sciences) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
CT1194C CAR-T(Hematology Hospital of Chinese Academy of Medical Sciences) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
CT1194C CAR-T(Hematology Hospital of Chinese Academy of Medical Sciences): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP
Read →
EVO200 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
9 min read
EVO200 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
EVO200: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
Read →